The salivary microbiota as a diagnostic indicator of oral cancer: A descriptive,non-randomized study of cancer-free and oral squamous cell carcinoma subjects

Background  

The purpose of the present investigation was to determine if the salivary counts of 40 common oral bacteria in subjects with an oral squamous cell carcinoma (OSCC) lesion would differ from those found in cancer-free (OSCC-free) controls.     

Phorbol esters stimulate the rapid release of choline from prelabelled cells

Evidence implicating the cell surface membrane as the primarysite of action of phorbol ester tumor promoters has led us tocharacterize early changes in phospholipid metabolism whichoccur in response to these compounds. When C3H10T mouse embryofibroblasts were incubated with [³H]choline for 24 h, {smalltilde}78% of the cell associated material was found in phosphatidylcholine and the remainder in sphingomyelin and the acid solublepool. Within 5 min of exposure of these prelabelled cells tothe potent tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate(PPD) the release of water soluble [³H] metabolites from cellsinto the medium was enhanced 2-fold and by 60–120 minthe release was 2–5 times that found in control cultures.The released material was identified by chromatography as cholineand phosphoryl choline. Evidence was obtained that this materialwas not derived exclusively from the acid soluble pool or fromthe degradation of labelled sphingomyelin. Choline metaboliterelease was concentration dependent between 10^–8 and 10^–7M TPA and was not associated with cell toxicity. Phorbol-12,13-didecanoate(PDD) was also active but 4PDD, which is not a tumor promoter,was inactive. Neither cyclohexlmide (4–40 µg/ml)nor cordycepln (4–40 µg/ml) blocked the TPA inducedrelease. The release was, however, temperature sensitive anddid not occur at 4°C. TPA did not induce the release of[³H]inositol from prelabelled phosphatidyl inositol. Although,the calcium ionophore A23187 [GenBank] induced the release of arachidonicacid from prelabelled cells it did not induce choline release.In addition, 5,8,11,14-eicosatetraynoic acid, which inhibitsboth lipoxygenase and cyclooxygenase activity, did not inhibitTPA stimulation of choline release. We propose that the bindingof TPA to cell surface receptors leads to a rapid activationof membrane associated phospholipase(s) that specifically degradephosphatidyl choline. This effect may be analogous to the abilityof other agonists to activate degradation of phosphatidyl inositol.     

Toxic cardiogenic shock in a patient receiving weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin

A 54-year-old man was treated with weekly 24-h infusion of high-dose 5-fluorouracil (2600 mg/m2) and leucovorin (100 mg/m2) for metastatic colon cancer. At first, he tolerated the treatment well and no significant toxicity was identified. After a total of eight courses of treatment, a stable disease was observed, but mild shortness of breath was found on occasion. The patient had no previous history of cardiac disease and the heart performance assessed by left ventricular ejection fraction before treatment was normal. Unfortunately, acute pulmonary edema with lethal cardiogenic shock occurred during the ninth course of treatment, in spite of intensive medical treatment. The chest X-ray showed extreme cardiomegaly. Repeated assessment of his heart function by echocardiogram and ventricular ejection fraction revealed a very poor cardiac performance. Toxic cardiogenic shock during weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin is extremely rare. To the best of our knowledge, no case has been reported in the English literature. We report a case and the relevant literature about the incidence, clinical picture and possible pathophysiology on 5-fluorouracil-related cardioxicity is reviewed.      

Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease

To characterize the heterogeneity of severe (type III) von Willebrand disease (vWD), plasma and platelet von Willebrand factor antigen (vWF:Ag) and ristocetin cofactor activity (Ricof) were measured in 28 obligatory heterozygotes (ie, parents or children of probands from 15 different kindreds with severe vWD). On the average, heterozygotes had low levels of vWF in both platelets and plasma. There was, however, considerable heterogeneity, with four distinct patterns. Eleven heterozygotes had concordant reduction of vWF:Ag and Ricof in both plasma and platelets; five had low levels of vWF:Ag and Ricof in plasma contrasting with normal levels in platelets; eight had a peculiar pattern, the reverse of the above (ie, low levels in platelets and normal levels in plasma); and in one, both vWF measurements were normal in plasma and platelets. These patterns were genetically determined: they were consistent in four couples of consanguineous heterozygotes and in two couples carrying the same gene deletion. Only the remaining three heterozygotes had no clearly identifiable pattern. Other findings of this study were that although most of the heterozygotes had normal bleeding times, the 7 of 28 who had prolonged bleeding times had concordantly low levels of vWF measurements in both plasma and platelets. In conclusion, this large series of obligatory heterozygotes provides evidence for phenotypic and genotypic heterogeneity of severe vWD.     

Carrier detection in hemophilia A: a cooperative international study. I. The carrier phenotype

Eight laboratories in six countries cooperated to clarify several issues concerning the phenotypes of heterozygous carriers of hemophilia "A." Plasma levels of factor VIII (F.VIII:C, formerly VIII:C) and von Willebrand factor (VWF:Ag, formerly VIIIR:Ag) of carriers and normal women were determined by various "in-house" methods; a single lyophilized plasma standard was used for all assays. Analysis of the collated data from 336 carriers (296 obligatory carriers and 40 sporadic carriers) and 137 normal women showed that there was no difference in the F.VIII:C levels of "paternal" carriers (women who had obtained the abnormal gene from their fathers) and "maternal" carriers. Neither was there a difference in the VWF:Ag levels of normal women and either type of carrier. Age was found to have a significant effect on both F.VIII:C and VWF:Ag, values being higher at very young and very old ages, the minima occurring in the 25- to 30-year range. ABO blood type had a striking effect. Women of types A, B, and AB (designated non- O in the study), both normals and carriers, had significantly higher levels of both factors than did women of type O. Analysis by laboratories showed that differences in mean levels of both factors between laboratories were highly significant. It was concluded that age, ABO blood type, and laboratory variation should be taken into account in carrier detection.     

Correlation of the exercise ST/HR slope with anatomic and radionuclide cineangiographic findings in stable angina pectoris

A rate-related change in ST-segment depression with exercise (ST/HR slope) of 6.0 microV/beat/min or more has been proposed as an accurate predictor of 3-vessel coronary artery disease (CAD). To further assess the accuracy and functional correlates of this method, exercise electrocardiograms were compared with radionuclide rest and exercise left ventricular (LV) ejection fraction (EF) and angiography in 35 patients with stable angina. The ST/HR slope was significantly increased in patients with 3-vessel CAD. An ST/HR slope of 6.0 or more identified 3-vessel CAD with a sensitivity of 89% and specificity of 88%. The predictive value for 3-vessel CAD was 73% owing to the presence of 3 false-positive slopes. The patients from whom these slopes were derived had functionally severe 2-vessel CAD, with an average decrease in exercise LVEF of 13%. Two of these 3 had additional left main CAD and the third has unsuspected additional aortic regurgitation. For the entire group, the exercise ST/HR slope was linearly related to the exercise change in LVEF (r = -0.55, p less than 0.001). Mean exercise change in LVEF for stable angina patients with ST/HR slopes of 4.5 or more was significantly different from that for patients with lower ST/HR slopes (-12 +/- 1% vs + 2 +/- 2%, p less than 0.0001). Thus, the ST/HR slope is both sensitive and specific for the identification of 3-vessel CAD, and high ST/HR slopes in patients with less extensive anatomic disease may predict functionally severe ischemia.